To identify the biomarker that potentially predicts the response to CYH33, the genomic alterations and gene expression at mRNA level were recruited from Cancer Cell Line Encyclopedia (CCLE) (https://depmap.org/portal/).21 Because PIK3CA mutation was utilized to stratify patients with hormone receptor-positive advanced breast cancer to receive alpelisib,22 the association between PIK3CA status and CYH33 activity was examined. This evidence concerns the gene PIK3CA and cancer.